HCPCS Level II code A9592 identifies Copper Cu-64 dotatate, a radiopharmaceutical administered at a 1 millicurie dose for diagnostic PET imaging of somatostatin receptor–positive tumors. This code matters nationally as molecular imaging agents like Cu‑64 dotatate enable targeted diagnostic evaluation of neuroendocrine and other somatostatin-receptor–expressing malignancies, influencing care pathways and utilization of advanced imaging services.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of coverage and reimbursement context, clinical purpose and typical care settings, and the operational considerations tied to radiopharmaceutical billing. The publication highlights benchmarks and policy-relevant points such as coding specificity for radiopharmaceuticals, payer coverage variability, and implications for site-of-service selection.

This summary is intended for administrators, coding professionals, and policy analysts seeking a clear, national-level briefing on HCPCS Level II code A9592, its clinical role in diagnostic PET imaging, and the payer landscape relevant to procurement and billing.